CRYAB and myeloid sarcoma: As shown here, the combined data from these studies led to the definition of a sub-immunogenic dose range of HspB5 that was considered suitable for testing in a subsequent randomized, placebo-controlled, double-blind Phase IIa study in RR-MS patients.